7.31 USD
↗ 0.01 (0.14%)AT CLOSE (03:59 PM EDT)
Arvinas, Inc
ARVNNASDAQ • USD
7.32
↗ 0.01 (0.14%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
7.32
↗ 0.01 (0.14%)
Market: CLOSED
Shares of Arvinas, Inc (ARVN) are trading at $7.28. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ARVN is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 26, 2026.
Open?$7.32
High?$7.41
Low?$7.23
Prev. Close?$7.30
Volume?746.8K
Avg. Volume?800.5K
VWAP?$7.31
Rel. Volume?0.93x
Bid / Ask
Bid?$6.82 × 1.0K
Ask?$7.32 × 1.1K
Spread?$0.50
Midpoint?$7.07
Valuation & Ratios
Market Cap?478.0M
Shares Out?64.5M
Float?54.6M
Float %?84.7%
P/E Ratio?51.39
P/B Ratio?0.85
EPS?$0.14
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Themes
Employees
246
Market Cap
477.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-09-27
Address
395 WINCHESTER AVE
NEW HAVEN, CT 06511
Phone: 203-535-1456
NEW HAVEN, CT 06511
Phone: 203-535-1456
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?9
Momentum?85
Short Sent.?54
Piotroski F-Score?6/9Mixed
Altman Z-Score?0.82Distress
Confidence?53%Low
Short InterestHigh
Short % of Float?10.24%High
Short Interest?5.6M
Days to Cover?8.2
Free Float54.6M
Avg Daily Volume684.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?7.91Strong
Quick Ratio?7.91Strong
Cash Ratio?1.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score87/100
P/E?51.4PRICEY▾
Peers100
S&P12
P/B?0.85CHEAP▾
Peers100
S&P97
P/S?1.51CHEAP▾
Peers100
S&P78
P/FCF?N/A▾
EV/EBITDA?-35.2CHEAP▾
S&P97
EV/Sales?1.21CHEAP▾
Peers100
S&P88
Returns & Efficiency
ROE?1.7%WEAK▾
Peers50
S&P17
ROA?1.4%WEAK▾
Peers50
S&P15
Cash Flow & Enterprise
FCF?$-208800000
Enterprise Value?$384.0M
Fundamentals ratios updated end of day